SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging after delivering a massive fiscal Q4 earnings beat and issuing aggressive FY2027 revenue guidance that far outpaced analyst projections. While the community is divided by skepticism over historical management transparency and potential dilution, many investors are cheering the company's record backlog and broadening enterprise demand as catalysts for a potential short squeeze.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending following a massive earnings beat that surpassed analyst expectations in both revenue and backlog, fueling intense debate between bulls banking on AI infrastructure demand and bears focused on the company's significant debt load and cash burn. The community is sharply divided, with traders closely watching the stock's volatility as it attempts to break through critical resistance levels following the positive financial results.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is facing significant selling pressure as investors react to a substantial reduction in full-year revenue guidance and concerns over management's ability to navigate market volatility. While the community remains divided between those frustrated by the lack of price transparency and institutional guidance and long-term believers who are leveraging the dip to accumulate shares in anticipation of critical mineral demand and potential government support.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is trending as investors rally ahead of upcoming quarterly results, fueled by a multi-million-dollar Israeli Ministry of Defense contract and a high short interest position that has sparked active discussion of a potential squeeze. The community is focused on the company's expanding defense and autonomous drone footprint, with many pointing to the stocks technical breakout potential and institutional partnerships as catalysts for a move toward double-digit pricing.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Investors are closely monitoring Sellas Life Sciences as they await the pivotal 80th event in the Phase 3 REGAL trial, with community sentiment increasingly focused on the possibility of a buyout or significant data catalyst given the ongoing quiet period. Discussions center on the unprecedented durability of patient survival, which some community members interpret as a signal of high clinical efficacy that could reshape the treatment landscape for AML patients.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is seeing increased community interest and bullish sentiment as investors eye a potential turnaround following a recent period of volatility. Market participants are actively tracking upcoming earnings and contract developments, with many debating the stock's long-term growth potential compared to other industry peers.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is seeing heavy engagement as investors analyze its recent earnings beat and strong forward guidance against a backdrop of ongoing sector-wide volatility. The community remains divided between optimism over the company's long-term leadership in AI data center optics and concerns regarding after-hours price action and potential overvaluation.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is experiencing high volatility as investors pivot between excitement over a major manufacturing campus expansion and fears surrounding short-seller allegations regarding company leadership and business relationships. The community is actively debating the stock's long-term potential as a critical supplier for aerospace and defense, with many traders looking for confirmation of support levels while anticipating a recovery from the recent sell-off.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is generating significant community conversation as investors speculate on potential price movements, with many highlighting upcoming space-related catalysts and long-term holding strategies. While some traders remain skeptical of current market conditions, others are actively debating the impact of upcoming legislative developments on the broader cryptocurrency sector.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is currently capturing significant market attention following a strong earnings report that featured a double-beat on both revenue and earnings, driven by robust guest traffic and effective expansion strategies. Community sentiment remains largely bullish as investors digest analyst upgrades and debate the company's premium valuation compared to other fast-casual leaders.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients...

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 28, 2026, that were previously approved by its Board of Directors under Sareptas 2024 Employment Commencement Incentive Plan, as amended, as a material inducement to...

Earnings Preview: Sarepta Therapeutics (SRPT) Q2 Earnings Expected to Decline

Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term?

Equity

Morgan Stanley said it remains cautious in the near term because of continued challenges in the company's Duchenne muscular dystrophy business.


Capricor Says FDA Used 'Obsolete' Analysis In Deramiocel Review – CAPR Stock Plummets After Agency Released Briefing Document

The FDA released briefing documents, raising concerns over whether Capricor’s lead therapy, Deramiocel, has demonstrated sufficient effectiveness in treating cardiomyopathy in patients with Duchenne muscular dystrophy.


Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Michael Severino, M.D., as chief executive officer, effective July 28, 2026. Severino, who was previously CEO of Tessera Therapeutics, will also join Sareptas...

$SRPT Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.05 down -102.49% YoY
• Reported revenue of $401.25M down -34.34% YoY
• Sarepta Therapeutics narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million for the full year.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$18.22
Prev Close	$17.18
Open	$17.23
Dividend Yield	0.00%
50-Day Moving Average	$16.89
Beta	1.23
Avg. Volume	3.16M
PE Ratio	-5.93

52-Week High	$25.32
52-Week Low	$14.68
Market Capitalization	$1.81B
EPS (Annual)	-$7.13
Price to Book	1.19
Revenue Per Employee	$2.63M

Feed

News

Sentiment

Earnings

Fundamentals

Info